Immunostimulator Broncho-Munal® is used in children from 12 years of age and adults.
• helps to strengthen the immune system in a natural (physiological) way;
• fights not only with viruses - the cause of colds, but also with bacteria - the cause of complications;
• helps to reduce the duration of the disease;
• reduces the need for antibiotics;
• reduces the frequency of SARS (“acute respiratory viral infection”) during the year by 36%;
• Helps reduce the risk of complications.
The drug can be used at any stage in the complex treatment of acute respiratory viral infections and colds.
To increase immunity, take 1 capsule 30 minutes before meals 1 time per day:
• in the complex treatment of respiratory infections - until the symptoms disappear (fever, runny nose, cough, etc.), but not less than 10 days.
• for the prevention of recurrent acute respiratory viral infections - three courses of 10 days with an interval between courses of 20 days.
1 capsule contains:
Active substance:
• bacterial lysates in the form of a standardized bacterial lyophilisate (OM-85) (OM-Pharma, Switzerland) - 7,000 mg:
• Haemophilus influenzae
• Streptococcus pneumoniae
• Streptococcus viridans
• Streptococcus pyogenes
• Klebsiella pneumoniae
• Klebsiella ozaenae
• Staphylococcus aureus
• Moraxella catarrhalis
Excipients: • propyl gallate (anhydrous) • sodium glutamate (anhydrous) • mannitol (as part of the active ingredient) • magnesium stearate • pregelatinized starch • mannitol
Capsule shell: • indigotin E132 • titanium dioxide E171 • gelatin
The drug Broncho-Munal® has an immunostimulating effect, strengthening the immune system against bacteria and viruses, respiratory tract infections.
After taking the capsule, the bacterial lysate accumulates in the Peyer's patches of the mucous membrane of the gastrointestinal tract, in particular, located in the small intestine. Antigen-presenting cells in Peyer's patches are activated by bacterial lysate and subsequently stimulate other cell types (B-lymphocytes) responsible for specific immunity.
This leads to an increase in the number of circulating B-lymphocytes, which leads to an increase in the production of polyclonal antibodies, especially serum IgG and IgA, secreted by the respiratory mucosa and salivary glands.
The drug also affects nonspecific immunity by stimulating leukocytes, which is characterized by an increase in the number of myeloid and lymphoid cells, as well as a selective increase in the expression of receptors on their surface.
Clinically, Broncho-Munal® reduces the frequency of acute respiratory tract infections, reduces the duration of their course, reduces the likelihood of exacerbations of chronic bronchitis, and also increases the body's resistance to infections of the respiratory system. This reduces the need for the use of other drugs, especially antibiotics.
